TREXAVIVE

A practical new treatment for complex MDD and PTSD

Built for complexity. **Ready for practice.**

Subcutaneous, non-sedating and now available via SAS and AP pathways.

Major depressive disorder presents in diverse and sometimes difficult-to-manage ways. Many patients cycle through medications and therapies with limited or short-lived benefit — or experience functional disruption due to side effects.

TREXAVIVE offers a new kind of option:

Originally developed to address unmet needs in MDD, TREXAVIVE is also being explored for trauma-related conditions, including PTSD.

- Non-sedating, non-psychoactive
- Subcutaneous administration
- Outpatient Ready - No hospital stay

HOW IT WORKS

Modulated care. **Measured results.**

TREXAVIVE combines two well-characterised compounds; flumazenil and low-dose naltrexone to help restore balance in key neurochemical pathways linked to depression and stress dysregulation.

» **GABA-A receptor modulation may help reverse maladaptive inhibitory signalling**

» **Opioid receptor antagonism may interrupt dysfunctional hedonic and stress circuits**

Together, these effects support clinical improvement without sedation, dissociation, or disruption — making TREXAVIVE appropriate for outpatient use.



CLINICAL ADVANTAGES

Supporting daily function—not just symptom relief.

TREXAVIVE is ideal for patients experiencing complex MDD presentations — especially where functional preservation and lifestyle compatibility are key considerations.

It is also showing promise in PTSD and related high-stress clinical profiles.

Key Features:

» **Subcutaneous injection. No IV, no clinic stay**

» **Non-sedating, non-dissociative**

» **Reported benefit up to 12–18 months after a single course**

» **Well-tolerated with minimal disruption to daily activities**

» **Appropriate for outpatient management of MDD and PTSD**

» **Accessible under SAS or AP prescribing frameworks**

TRD is not a requirement for consideration but patients with treatment histories involving multiple failed interventions may particularly benefit.

Available via SAS and Authorised Prescriber **pathways**

TREXAVIVE can be prescribed by eligible Australian clinicians through the TGA's Special Access Scheme (Category B) or the Authorised Prescriber (AP) pathway. These regulatory channels are intended to support patients who need access beyond first-line options.

TREXAPHARM provides full support for clinical implementation, including:

- Scientific summaries and prescribing guidance
- Dosing and administration protocols
- Patient information and consent materials
- Case review support and liaison assistance

TREXAVIVE is designed for straightforward integration into psychiatric and specialist care — no clinic infrastructure or monitoring required.

To request a prescriber pack or speak with our liaison team, visit trexavive.com/hcp or scan the QR code below.

Get clinical information, prescribing guidance, and support at **trexavive.com/hcp**

Developed with purpose. Anchored in science.

TREXAVIVE